LK-A exhibits anti-tumour activity in vivo . Mice bearing CNE2 nasopharyngeal carcinoma tumours were treated with LK-A (6 mg/Kg QW or 6 mg/Kg QOD), Paclitaxel or saline for three weeks. (A, B) Graph and images depicted the tumour volumes (mm3) over time (data are shown as the mean tumour volume ± SD). (C) Bar chart shows the weight of tumours from mice (data are shown as the mean tumour weight ± SEM *p < 0.05). (D) The graph shows the weight change of the nude mice. On first day there are no differences between the four groups. On the 28th day, there is a significant change in body weight in mice treated with LK-A (6 mg/Kg QOD) or Paclitaxel compared with mice treated with LK-A (6 mg/Kg QW) or the saline group (*p < 0.05). However, there is no difference between the LK-A-treated (6 mg/Kg QOD) and Paclitaxel-treated groups.